ByteDance has spun off its Shanghai-based AI drug discovery arm, Anew Labs, raising $290 million at a $1.5 billion valuation from investors including HSG, IDG Capital, and Hillhouse, while retaining a 56% majority stake.
FireBrief
FireBrief